These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 22166436)
21. Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway. Marchetti B; Serra PA; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Cioni S; Gennuso F; Rocchitta G; Desole MS; Mazzarino MC; Miele E; Morale MC Ann N Y Acad Sci; 2005 Dec; 1057():296-318. PubMed ID: 16399902 [TBL] [Abstract][Full Text] [Related]
22. Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats. Singh S; Mishra A; Srivastava N; Shukla R; Shukla S Mol Neurobiol; 2018 Jan; 55(1):583-602. PubMed ID: 27975173 [TBL] [Abstract][Full Text] [Related]
23. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Collins LM; Toulouse A; Connor TJ; Nolan YM Neuropharmacology; 2012 Jun; 62(7):2154-68. PubMed ID: 22361232 [TBL] [Abstract][Full Text] [Related]
24. Pathogenic role of glial cells in Parkinson's disease. Teismann P; Tieu K; Cohen O; Choi DK; Wu DC; Marks D; Vila M; Jackson-Lewis V; Przedborski S Mov Disord; 2003 Feb; 18(2):121-9. PubMed ID: 12539204 [TBL] [Abstract][Full Text] [Related]
25. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Ferrari CC; Pott Godoy MC; Tarelli R; Chertoff M; Depino AM; Pitossi FJ Neurobiol Dis; 2006 Oct; 24(1):183-93. PubMed ID: 16901708 [TBL] [Abstract][Full Text] [Related]
26. A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. Kim YS; Choi DH; Block ML; Lorenzl S; Yang L; Kim YJ; Sugama S; Cho BP; Hwang O; Browne SE; Kim SY; Hong JS; Beal MF; Joh TH FASEB J; 2007 Jan; 21(1):179-87. PubMed ID: 17116747 [TBL] [Abstract][Full Text] [Related]
27. Running exercise protects the substantia nigra dopaminergic neurons against inflammation-induced degeneration via the activation of BDNF signaling pathway. Wu SY; Wang TF; Yu L; Jen CJ; Chuang JI; Wu FS; Wu CW; Kuo YM Brain Behav Immun; 2011 Jan; 25(1):135-46. PubMed ID: 20851176 [TBL] [Abstract][Full Text] [Related]
28. A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C). Smith GA; Rocha EM; Rooney T; Barneoud P; McLean JR; Beagan J; Osborn T; Coimbra M; Luo Y; Hallett PJ; Isacson O PLoS One; 2015; 10(3):e0121072. PubMed ID: 25815475 [TBL] [Abstract][Full Text] [Related]
29. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Hald A; Lotharius J Exp Neurol; 2005 Jun; 193(2):279-90. PubMed ID: 15869932 [TBL] [Abstract][Full Text] [Related]
30. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons. Hill WD; Arai M; Cohen JA; Trojanowski JQ J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049 [TBL] [Abstract][Full Text] [Related]
31. Inflammation in Parkinson's disease: causative or epiphenomenal? Hald A; Van Beek J; Lotharius J Subcell Biochem; 2007; 42():249-79. PubMed ID: 17612055 [TBL] [Abstract][Full Text] [Related]
32. Microglial activation is not prevented by tacrolimus but dopamine neuron damage is reduced in a rat model of Parkinson's disease progression. Wright AK; Miller C; Williams M; Arbuthnott G Brain Res; 2008 Jun; 1216():78-86. PubMed ID: 18495090 [TBL] [Abstract][Full Text] [Related]
33. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease. Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211 [TBL] [Abstract][Full Text] [Related]
34. Targeting metabolic inflammation in Parkinson's disease: implications for prospective therapeutic strategies. Lu M; Hu G Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):577-85. PubMed ID: 22126374 [TBL] [Abstract][Full Text] [Related]
35. Resolvin D2 recovers neural injury by suppressing inflammatory mediators expression in lipopolysaccharide-induced Parkinson's disease rat model. Tian Y; Zhang Y; Zhang R; Qiao S; Fan J Biochem Biophys Res Commun; 2015 May; 460(3):799-805. PubMed ID: 25824039 [TBL] [Abstract][Full Text] [Related]
36. [Role of microglial activation induced by α-synuclein in pathogenesis of Parkinson's disease]. Qiao S; Luo JH; Jin JH Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Mar; 41(2):210-4. PubMed ID: 22499522 [TBL] [Abstract][Full Text] [Related]
37. Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease. Pradhan S; Andreasson K Exp Neurol; 2013 Mar; 241():148-55. PubMed ID: 23261765 [TBL] [Abstract][Full Text] [Related]
38. Extracellular α-synuclein--a possible initiator of inflammation in Parkinson's disease. Ren WQ; Tian ZM; Yin F; Sun JZ; Zhang JN Pharmazie; 2016 Feb; 71(2):51-5. PubMed ID: 27004367 [TBL] [Abstract][Full Text] [Related]
39. Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Wang Q; Liu Y; Zhou J Transl Neurodegener; 2015; 4():19. PubMed ID: 26464797 [TBL] [Abstract][Full Text] [Related]
40. Role of cytokines in inflammatory process in Parkinson's disease. Sawada M; Imamura K; Nagatsu T J Neural Transm Suppl; 2006; (70):373-81. PubMed ID: 17017556 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]